Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.

Subjects who develop type 2 diabetes have a complex phenotype with defects in insulin secretion, increased hepatic glucose production, and resistance to the action of insulin, all of which contribute to the development of overt hyperglycemia. Although the precise mechanisms whereby these three factors interact to produce glucose intolerance and diabetes are uncertain, it has been suggested that the final common pathway responsible for the development of type 2 diabetes is the failure of the pancreatic β cell to compensate for insulin resistance (1). Here, we review evidence for this model from both human and animal studies, and we consider the effects of specific drug treatments and of heightened FFA levels on insulin sensitivity and insulin secretion in individuals at risk for type 2 diabetes. Coleman and coworkers (2), drawing on their work with the ob/ob mouse, first proposed that a failure of β-cell compensation for insulin resistance is responsible for the development of type 2 diabetes. When insulin-resistant ob/ob mice, which provide a genetic model of obesity, were bred with mice of different strains, the phenotypes of the progeny differed depending on their genetic background. Mice carrying the ob mutation in the C57BL/6 background had relatively normal blood glucose levels, whereas in the C57Ks background the animals developed overt hyperglycemia. The major difference between these two mouse strains lay in their β-cell responses. The nondiabetic C57BL/6 mice underwent a marked expansion of β-cell mass, whereas C57Ks animals showed histologic evidence of islet degeneration, degranulation, and progressive atrophy. The C57Ks animals accordingly had insulin levels about one-tenth those of the C57BL/6 animals, and these levels declined progressively with age. These data indicated that the genetic background on which insulin resistance develops influences the adequacy of pancreatic β-cell compensation for insulin resistance, and hence the predisposition to diabetes.

[1]  M. Stern.  Strategies and prospects for finding insulin resistance genes. , 2000, The Journal of clinical investigation.

[2]  Y. Kido,et al.  Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. , 2000, The Journal of clinical investigation.

[3]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .

[4]  D. Hanahan,et al.  Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. , 1999, The Journal of clinical investigation.

[5]  R. Bergman,et al.  Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. , 1999, American journal of physiology. Endocrinology and metabolism.

[6]  C. Kahn,et al.  Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes , 1999, Cell.

[7]  Gang Xu,et al.  Insulin Receptor Signaling in the β-Cell Influences Insulin Gene Expression and Insulin Content: Evidence for Autocrine β-Cell Regulation , 1998, Diabetes.

[8]  P. Berggren,et al.  Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. , 1998, Molecular cell.

[9]  B. Kahn.  Type 2 Diabetes: When Insulin Secretion Fails to Compensate for Insulin Resistance , 1998, Cell.

[10]  K. Polonsky,et al.  Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. , 1998, Diabetes.

[11]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[12]  G. Ward,et al.  Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients , 1997, Diabetologia.

[13]  J. Sturis,et al.  Changes in Pancreatic Islet Glucokinase and Hexokinase Activities With Increasing Age, Obesity, and the Onset of Diabetes , 1997, Diabetes.

[14]  K. Polonsky,et al.  Troglitazone Improves Defects in Insulin Action , Insulin Secretion , Ovarian Steroidogenesis , and Fibrinolysis in Women with Polycystic Ovary Syndrome * , 1997 .

[15]  K. Polonsky,et al.  Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. , 1997, The Journal of clinical endocrinology and metabolism.

[16]  M. Byrne,et al.  Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. , 1997, The Journal of clinical investigation.

[17]  J. McGarry,et al.  Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. , 1996, The Journal of clinical investigation.

[18]  M. Byrne,et al.  Elevated plasma glucose 2 h postchallenge predicts defects in beta-cell function. , 1996, The American journal of physiology.

[19]  J. H. Johnson,et al.  Defective fatty acid-mediated beta-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. , 1996, The Journal of biological chemistry.

[20]  C. Newgard,et al.  Differential Effects of Overexpressed Glucokinase and Hexokinase I in Isolated Islets , 1996, The Journal of Biological Chemistry.

[21]  M. Stoffel,et al.  Evolution of β-Cell Dysfunction in the Male Zucker Diabetic Fatty Rat , 1995, Diabetes.

[22]  M. Byrne,et al.  Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. , 1995, The Journal of clinical investigation.

[23]  J. Sturis,et al.  Defects in Insulin Secretion and Action in Women With a History of Gestational Diabetes , 1995, Diabetes.

[24]  C. Newgard,et al.  Pancreatic -Cells in Obesity , 1995, The Journal of Biological Chemistry.

[25]  J. H. Johnson,et al.  Pancreatic beta-cells in obesity. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. , 1995, The Journal of biological chemistry.

[26]  J. H. Johnson,et al.  Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. Enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. , 1994, The Journal of biological chemistry.

[27]  R. Bergman,et al.  Quantification of the Relationship Between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic Function , 1993, Diabetes.

[28]  J. Sturis,et al.  Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.

[29]  K. Polonsky,et al.  Defects in beta-cell function in functional ovarian hyperandrogenism. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  M. Mozzoli,et al.  Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. , 1991, The Journal of clinical investigation.

[31]  G. Boden,et al.  Effects of Lipid on Basal Carbohydrate Metabolism in Normal Men , 1991, Diabetes.

[32]  R N Bergman,et al.  Insulin sensitivity and B‐cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes , 1991, American journal of obstetrics and gynecology.

[33]  V. Grill,et al.  A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation. , 1990, Endocrinology.

[34]  B H Frank,et al.  Quantitative study of insulin secretion and clearance in normal and obese subjects. , 1988, The Journal of clinical investigation.

[35]  D. Steinberg,et al.  Stimulation of insulin secretion by long-chain free fatty acids. A direct pancreatic effect. , 1973, The Journal of clinical investigation.

[36]  S. Fajans,et al.  An Approach to the Prediction of Diabetes Mellitus by Modification of the Glucose Tolerance Test with Cortisone , 1954, Diabetes.